U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT06872073) titled 'Assessment of Methotreaxate-induced Liver Fibrosis by Transient Elastography and Serological Markers' on March 07.
Brief Summary: Methotrexate (MTX), a folic acid analogue, inhibits the synthesis of purines and pyrimidines and is widely used in the treatment of chronic inflammatory diseases, particularly Rheumatoid arthritis (RA). It is typically the first-line drug for RA management. However, prolonged MTX use is associated with hepatotoxicity, including liver fibrosis (LF), which necessitates regular monitoring, especially of liver function tests MTX-induced liver injury has been recognized since the early 1970and numerous studie...